Evidence map›Paper›PMID 37941453›Full record

ReviewBiology of reproduction2024

Reversible female contraceptives: historical, current, and future perspectives†.

Brooke E Barton, Jeffery A Erickson, Stephanie I Allred, Jenna M Jeffries, Kalli K Stephens, Mark I Hunter, Kirby A Woodall, Wipawee Winuthayanon

Open access · hybridAbstract readReview
In one paragraph

Review in Biology of reproduction, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Brooke E BartonSchool of Medicine, University of Washington, Seattle, WA, USA.
Jeffery A EricksonOB/GYN & Women's Health, School of Medicine, University of Missouri, Columbia, MO, USA.
Stephanie I AllredOB/GYN & Women's Health, School of Medicine, University of Missouri, Columbia, MO, USA.
Jenna M JeffriesCollege of Art & Science, Washington State University, Pullman, WA, USA.
Kalli K StephensOB/GYN & Women's Health, School of Medicine, University of Missouri, Columbia, MO, USA.
Mark I HunterOB/GYN & Women's Health, School of Medicine, University of Missouri, Columbia, MO, USA.
Kirby A WoodallOB/GYN & Women's Health, School of Medicine, University of Missouri, Columbia, MO, USA.
Wipawee WinuthayanonOB/GYN & Women's Health, School of Medicine, University of Missouri, Columbia, MO, USA.
University of Missouri Health System · USUniversity of Washington · USWashington State University · US

Funding

Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptiveR01HD108198 · NICHD · WASHINGTON STATE UNIVERSITY · PI MARTIN M. MATZUK, OV D SLAYDEN · 2022 to 2026
$3.7M
The actions of steroid hormones on oviduct functionR01HD097087 · NICHD · WASHINGTON STATE UNIVERSITY · PI WINUTHAYANON, WIPAWEE · 2019 to 2023
$1.7M
NICHD NIH HHS R01 HD097087NICHD NIH HHS R01 HD108198NIH HHS R01HD097087
6 · The paper itself

Abstract

Contraception is a practice with extensive and complicated social and scientific histories. From cycle tracking, to the very first prescription contraceptive pill, to now having over-the-counter contraceptives on demand, family planning is an aspect of healthcare that has undergone and will continue to undergo several transformations through time. This review provides a comprehensive overview of current reversible hormonal and non-hormonal birth control methods as well as their mechanism of action, safety, and effectiveness specifically for individuals who can become pregnant. Additionally, we discuss the latest Food and Drug Administration (FDA)-approved hormonal method containing estetrol and drospirenone that has not yet been used worldwide as well as the first FDA-approved hormonal over-the-counter progestin-only pills. We also review available data on novel hormonal delivery through microchip, microneedle, and the latest FDA-approved non-hormonal methods such as vaginal pH regulators. Finally, this review will assist in advancing female contraceptive method development by underlining constructive directions for future pursuits. Information was gathered from the NCBI and Google Scholars databases using English and included publications from 1900 to present. Search terms included contraceptive names as well as efficacy, safety, and mechanism of action. In summary, we suggest that investigators consider the side effects and acceptability together with the efficacy of contraceptive candidate towards their development.

Indexed as

Contraceptive Agents, FemaleContraceptionFemaleHumansPregnancyUnited StatesContraceptive Agents, Femalebirth controlcontraceptionhormonalnon-hormonalpregnancy preventionthe pill

Identifiers

PMID37941453
PMCPMC10790348
OpenAlexW4388515783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.